Posted by Michael Wonder on 25 Jul 2016
CHMP issues positive opinion for Orencia (abatacept) in the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate in the EU
25 July 2016 - Bristol-Myers Squibb Company today announced that the CHMP of the EMA has issued a positive opinion, recommending the approval of Orencia (abatacept) intravenous infusion and subcutaneous injection, in combination with methotrexate, for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
This CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.
